Rising Cases of Scleroderma and Increasing Access to Medical Insurance in the U.S are Expected to drive the Global Scleroderma Therapeutics Market in the forecast period of 2019 to 2026

Global Scleroderma Therapeutics Market is projected to grow at a steady CAGR of 5.2% in the forecast period of 2019 to 2026.

Access Full Report at https://www.databridgemarketresearch.com/reports/global-scleroderma-therapeutics-market

Drivers: Global Scleroderma Therapeutics Market

  • Rising cases of scleroderma
  • Increasing access to medical insurance in the U.S.


  • Lack of curative treatment and counterfeit products


  • Unmet patient needs in systemic sclerosis


  • Side effects of drugs

Market Trends

  • On the basis of type, the market is segmented into localized scleroderma and systemic scleroderma. The systemic scleroderma is expected to grow at the highest CAGR in the forecast period of 2019 to 2026.
  • On the basis of treatment type, the market is segmented into drug treatment, surgery treatment and therapy
  • On the basis of end user, the global scleroderma therapeutics market is segmented into hospital, speciality clinics, homecare settings and others

Major Players: Global Scleroderma Therapeutics Market

The key market players for global collaborative robot market are listed below:

  • Argentis Pharmaceuticals, LLC.
  • F. Hoffmann-La Roche Ltd
  • AbbVie Inc.
  • Pfizer Inc.
  • Sanofi
  • viDA Therapeutics Inc.
  • Novartis AG
  • Active Biotech AB.
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc.
  • Johnson & Johnson Services, Inc.
  • AstraZeneca
  • Daval International Limited